Dr Reddy's Labs launches Colchicine Tablets in US
Dr. Reddy's Colchicine is available in 0.6 mg tablets in bottle count sizes of 30s and 1 00s
Hyderabad: Dr. Reddy's Laboratories Ltd. has announced the launch of Colchicine Tablets USP, a therapeutic equivalent generic version of Colcrys® (colchicine) Tablets, 0.6 mg, approved by the U.S. Food and Drug Administration (USFDA).
The Colcrys® brand and the generic market had U.S. sales of approximately $491 million MAT for the most recent twelve months ending in March 2020 according to IQVIA Health*.
Dr. Reddy's Colchicine is available in 0.6 mg tablets in bottle count sizes of the 30s and 1 00s.
Dr. Reddy's Laboratories Ltd. is an integrated pharmaceutical company headquartered in Hyderabad, committed to providing affordable and innovative medicines for healthier lives.
Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology.
The Company's markets include – USA, India, Russia & CIS countries, and Europe.
Read also: Dr Reddy's Labs gets USFDA EIR for IPDO facility
